News

Tyvaso DPI Earns FDA Priority Review Status

The U.S. Food and Drug Administration (FDA) has granted priority review status to the application seeking approval of Tyvaso DPI — a dry powder inhaled formulation of treprostinil — for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Priority review shortens…

Research Sheds Light on Potential Immune Changes in IPAH

A combination of lung injury and increased activation of B-cells — immune cells responsible for antibody production — was sufficient to promote symptoms of pulmonary hypertension (PH) in mice, a study shows. In addition, increased B-cell activation and higher levels of immune cells known to promote antibody production also were…

Prostacyclin Therapy, Expert Care Help in Pregnancy With PAH

Despite a high-risk of serious complications, 10 women with moderate to severe pulmonary arterial hypertension (PAH) had a successful pregnancy and delivery, according to a single center study. The patients were managed with prostacyclin therapy in addition to PAH-specific treatments during pregnancy and specialized care. Most transitioned to oral…

Text-based Intervention Helped Increase Physical Activity

A three-month unsupervised health intervention based on a commercial activity tracker and motivational texts significantly increased daily step counts and improved quality of life in adults with pulmonary arterial hypertension (PAH), according to data from a single-center trial in the U.S. Since physical activity has been shown to…